Enhanced TGF-β/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor

Clinical and Experimental Nephrology

Volumn 11, Issue 1, 2007, Pages 77-87

  Okazaki, Yuko ^a   Yamasaki, Yasushi ^a   Uchida, Haruhito A ^a   Okamoto, Kazunori ^a   Satoh, Minoru ^a   Maruyama, Keisuke ^a   Maeshima, Yohei ^a   Sugiyama, Hitoshi ^a   Sugaya, Takeshi ^b   Kashihara, Naoki ^c   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b RIKEN KOBE INSTITUTE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Diabetic nephropathy; Smad; TGF receptor type I and type II; Transforming growth factor

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; MESSENGER RNA; SMAD PROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33947511782     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-006-0456-1     Document Type: Article

References (42)

1. G Wolf FN Ziyadeh 1999 Molecular mechanisms of diabetic renal hypertrophy Kidney Int 56 393 405
2. H Makino N Kashihara H Sugiyama K Kanao T Sekikawa K Okamoto 1996 Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes Diabetes 45 488 95
3. AE Raptis G Viberti 2001 Pathogenesis of diabetic nephropathy Exp Clin Endocrinol Diabetes 109 Suppl 2 S424 37
4. G Wolf FN Ziyadeh 1997 The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms Am J Kidney Dis 29 153 63
5. DJ Leehey AK Singh N Alavi R Singh 2000 Role of angiotensin II in diabetic nephropathy Kidney Int Suppl 77 S93 8
6. C Hill A Logan C Smith H Gronbaek A Flyvbjerg 2001 Angiotensin-converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats Diabetologia 44 495 500
7. H Peters WA Border NA Noble 1998 Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade Kidney Int 54 1570 80
8. EJ Lewis LG Hunsicker RP Bain RD Rohde 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Collaborative Study Group N Engl J Med 329 1456 62
9. BM Brenner ME Cooper D de Zeeuw WF Keane WE Mitch HH Parving 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 9
10. JH Song SH Cha HJ Lee SW Lee GH Park MJ Kim 2006 Effect of low-dose dual blockade of the renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease Nephrol Dial Transplant 21 683 9
11. T Yamamoto NA Noble AH Cohen CC Nast A Hishida LI Gold 1996 Expression of transforming growth factor-beta isoforms in human glomerular diseases Kidney Int 49 461 9
12. S Kagami WA Border DE Miller NA Noble 1994 Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells J Clin Invest 93 2431 7
13. T Yamamoto T Nakamura NA Noble E Ruoslahti WA Border 1993 Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy Proc Natl Acad Sci USA 90 1814 8
14. WA Border T Yamamoto NA Noble 1996 Transforming growth factor beta in diabetic nephropathy Diabetes Metab Rev 12 309 39
15. W Wang V Koka HY Lan 2005 Transforming growth factor-beta and Smad signalling in kidney diseases Nephrology (Carlton) 10 48 56
16. E Gagliardini A Benigni 2006 Role of anti-TGF-beta antibodies in the treatment of renal injury Cytokine Growth Factor Rev 17 89 96
17. M Stopa D Anhuf L Terstegen P Gatsios AM Gressner S Dooley 2000 Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation J Biol Chem 275 29308 17
18. K Okamoto N Kashihara H Sugiyama T Sekikawa Y Maeshima K Kanao 1997 Suppression of phenotypic alteration of mesangial cells in diabetes induced in angiotensin II type 1a receptor deficient mice J Am Soc Nephrol 8 644A
19. T Sugaya S Nishimatsu K Tanimoto E Takimoto T Yamagishi K Imamura 1995 Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia J Biol Chem 270 18719 22
20. AA Like AA Rossini 1976 Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus Science 193 415 7
21. Y Maeshima N Kashihara T Yasuda H Sugiyama T Sekikawa K Okamoto 1998 Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo J Clin Invest 101 2589 97
22. M Satoh N Kashihara Y Yamasaki K Maruyama K Okamoto Y Maeshima 2001 Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice J Am Soc Nephrol 12 317 25
23. S Okada K Shikata M Matsuda D Ogawa H Usui Y Kido 2003 Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes Diabetes 52 2586 93
24. T Yamamoto T Watanabe N Ikegaya Y Fujigaki K Matsui H Masaoka 1998 Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis J Am Soc Nephrol 9 2253 61
25. C Hill A Flyvbjerg H Gronbaek J Petrik DJ Hill CR Thomas 2000 The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats Endocrinology 141 1196 208
26. FN Ziyadeh DC Han 1997 Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology Kidney Int Suppl 60 S7 11
27. SW Hong M Isono S Chen MC Iglesias-De La Cruz DC Han FN Ziyadeh 2001 Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse Am J Pathol 158 1653 63
28. A Erman S Veksler U Gafter G Boner C Wittenberg DJ van Dijk 2004 Renin-angiotensin system blockade prevents the increase in plasma transformIng growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin diabetic rat J Renin Angiotensin Aldosterone Syst 5 146 51
29. J Liao M Kobayashi Y Kanamuru S Nakamura Y Makita K Funabiki 2003 Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice J Nephrol 16 841 9
30. JY Guh ML Yang YL Yang CC Chang LY Chuang 1996 Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions J Am Soc Nephrol 7 1207 15
31. L Mishra B Marshall 2006 Adaptor proteins and ubiquinators in TGF-beta signaling Cytokine Growth Factor Rev 17 75 87
32. M Isono S Chen SW Hong MC Iglesias-de la Cruz FN Ziyadeh 2002 Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells Biochem Biophys Res Commun 296 1356 65
33. HC Huang PA Preisig 2000 G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth Kidney Int 58 162 72
34. M Ruiz-Ortega M Ruperez V Esteban J Rodriguez-Vita E Sanchez-Lopez G Carvajal 2006 Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases Nephrol Dial Transplant 21 16 20
35. J Rodriguez-Vita E Sanchez-Lopez V Esteban M Ruperez J Egido M Ruiz-Ortega 2005 Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism Circulation 111 2509 17
36. JH Li XR Huang HJ Zhu M Oldfield M Cooper LD Truong 2004 Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease Faseb J 18 176 8
37. J Yue KM Mulder 2000 Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway J Biol Chem 275 30765 73
38. W Wang XR Huang E Canlas K Oka LD Truong C Deng 2006 Essential role of Smad3 in angiotensin II-induced vascular fibrosis Circ Res 98 1032 9
39. T Matsusaka Y Miyazaki I Ichikawa 2002 The renin angiotensin system and kidney development Annu Rev Physiol 64 551 61
40. W Wang XR Huang AG Li F Liu JH Li LD Truong 2005 Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7 J Am Soc Nephrol 16 1371 83
41. K Uchida H Suzuki T Ohashi K Nitta W Yumura H Nihei 2001 Involvement of MAP kinase cascades in Smad7 transcriptional regulation Biochem Biophys Res Commun 289 376 81
42. A Nakao M Fujii R Matsumura K Kumano Y Saito K Miyazono 1999 Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice J Clin Invest 104 5 11